STOCK TITAN

Kestra Medical Technologies (KMTS) insider schedules 2,380-share stock sale after award vesting

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Kestra Medical Technologies reports that an affiliate plans to sell 2,380 shares of common stock through Merrill Lynch on August 3, 2026 on NASDAQ, with an indicated aggregate market value of $56,551.44. These shares relate to performance share unit awards that vested on July 17, 2026 and were granted under the issuer’s equity compensation plan. The notice also lists prior sales by Timothy Moran of 4,117 shares for $93,758.64 on July 30, 2026 and 8,759 shares for $198,000.29 on July 31, 2026.

Positive

  • None.

Negative

  • None.
Planned shares to be sold 2,380 shares Common stock to be sold through Merrill Lynch on August 3, 2026
Aggregate market value of planned sale $56,551.44 Estimated value of 2,380 shares of common stock
Vesting date of performance share units 07/17/2026 Date performance share unit awards vested into common stock
Shares sold on July 30, 2026 4,117 shares Common stock sold by Timothy Moran
Proceeds on July 30, 2026 $93,758.64 Value of 4,117 shares of common stock sold
Shares sold on July 31, 2026 8,759 shares Common stock sold by Timothy Moran
Proceeds on July 31, 2026 $198,000.29 Value of 8,759 shares of common stock sold
performance share unit awards financial
"Vesting of performance share unit awards"
equity compensation plan financial
"Granted as part of issuer equity compensation plan"
A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.
aggregate market value financial
"2380 | 56551.44 | 58602497 | 08/03/2026 | NASDAQ"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What stock sale is being reported for Kestra Medical Technologies (KMTS)?

A planned sale of 2,380 shares of Kestra Medical Technologies common stock is reported, to be executed through Merrill Lynch on August 3, 2026 on NASDAQ, with an aggregate market value of $56,551.44.

How were the 2,380 Kestra Medical Technologies (KMTS) shares obtained?

The 2,380 shares come from the vesting of performance share unit awards on July 17, 2026. These awards were originally granted under the issuer’s equity compensation plan, then converted into common stock upon vesting.

Which prior Kestra Medical Technologies (KMTS) stock sales are disclosed?

The disclosure lists Timothy Moran’s sales of 4,117 shares for $93,758.64 on July 30, 2026 and 8,759 shares for $198,000.29 on July 31, 2026, both involving Kestra Medical Technologies common stock.

Who is the broker for the planned Kestra Medical Technologies (KMTS) share sale?

The planned sale of 2,380 common shares will be handled by Merrill Lynch, located at 225 Liberty Street, Floor 37, New York, NY 10281, with the transaction expected to occur on NASDAQ on August 3, 2026.

What type of awards underlie the planned Kestra Medical Technologies (KMTS) share sale?

The planned sale relates to performance share unit awards that vested on July 17, 2026. These units were granted as part of the issuer equity compensation plan and converted into common stock before the reported sale.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature